```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7542 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7542

   To amend the Public Health Service Act to provide for congenital 
                 Cytomegalovirus screening of newborns.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 5, 2024

  Mr. Lawler (for himself and Mr. Landsman) introduced the following 
    bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
   To amend the Public Health Service Act to provide for congenital 
                 Cytomegalovirus screening of newborns.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as ``Stop CMV Act of 2024''.

SEC. 2. SCREENING OF CONGENITAL CYTOMEGALOVIRUS.

    Part A of title XI of the Public Health Service Act is amended by 
inserting after section 1116 (42 U.S.C. 300b-15) the following:

``SEC. 1116A. SCREENING OF CONGENITAL CYTOMEGALOVIRUS.

    ``(a) In General.--Each hospital or other health care entity caring 
for infants who are 21 days or less of age (as designated by the 
Secretary) may administer, or cause to have administered, to every such 
infant in its care a test for congenital Cytomegalovirus in accordance 
with this section.
    ``(b) Process.--
            ``(1) In general.--In carrying out this section, the chief 
        executive officer for health in each State may prescribe 
        standards and procedures for the administration of testing 
        under subsection (a), including recording the results of such 
        tests, tracking activities, conducting follow-up reviews, and 
        carrying out educational activities.
            ``(2) Dissemination of information.--In carrying out this 
        section, the chief executive officer for health in each State 
        may prescribe standards and procedures setting forth the manner 
        in which testing information is disseminated to a parent or 
        guardian of the infant to be tested.
            ``(3) Failure to prescribe.--If a State has not prescribed 
        standards and procedures that are approved as provided for in 
        paragraph (4) by the date that is 2 years after the date of 
        enactment of the Stop CMV Act of 2024, the Discretionary 
        Advisory Committee on Heritable Disorders in Newborns and 
        Children established under section 1111 (referred to in this 
        section as the `Advisory Committee') shall prescribe 
        appropriate standards and procedures which may be implemented 
        by such State.
            ``(4) Review and approval.--The standards and procedures 
        prescribed under this subsection shall be subject to review and 
        approval by the Advisory Committee. In reviewing or prescribing 
        standards and procedures as required under this subsection, the 
        Advisory Committee shall consider standards and procedures 
        adopted in other States with respect to the screening of 
        congenital Cytomegalovirus, the standards and procedures 
        adopted in such State with respect to the screening of infants 
        for other heritable diseases, and any scientific evidence the 
        Advisory Committee considers relevant to provide for the 
        screening of infants for congenital Cytomegalovirus.
    ``(c) Grants.--
            ``(1) Health resources and services administration.--
                    ``(A) In general.--The Secretary, acting through 
                the Administrator of the Health Resources and Services 
                Administration (referred to in this paragraph as the 
                `Secretary'), shall award grants to States that 
                prescribe standards and procedures in accordance with 
                paragraphs (1) and (2), to be distributed by the States 
                to entities described in subsection (a) to administer 
                tests in accordance with that subsection.
                    ``(B) Authorization of appropriations.--There is 
                authorized to be appropriated to carry out subparagraph 
                (A) such sums as may be necessary for each of fiscal 
                years 2023 and 2024.
            ``(2) Centers for disease control and prevention.--
                    ``(A) In general.--The Secretary, acting through 
                the Director of the Centers for Disease Control and 
                Prevention, shall award grants to, or enter into 
                cooperative agreements with, States to provide 
                technical assistance to State agencies or designated 
                entities of States--
                            ``(i) to develop, maintain, and improve 
                        data collection systems relating to congenital 
                        Cytomegalovirus; and
                            ``(ii) to assist in the education and 
                        training of health care providers, patients, 
                        and the general public regarding the risk 
                        reduction or prevention, symptoms, diagnosis, 
                        and treatment of congenital Cytomegalovirus, 
                        including, as necessary, through the 
                        publication of scientific, evidence-based 
                        educational materials on Internet webpages 
                        maintained by State agencies or designated 
                        entities of States.
                    ``(B) Authorization of appropriations.--There is 
                authorized to be appropriated to carry out subparagraph 
                (A) such sums as may be necessary for each of fiscal 
                years 2023 and 2024.
            ``(3) National institutes of health.--The Director of the 
        National Institutes of Health shall--
                    ``(A) for the purposes of this section, establish a 
                program, or expand existing programs, of research and 
                development on the efficacy of new screening techniques 
                and technology relating to congenital Cytomegalovirus, 
                including clinical studies of screening methods, 
                studies on efficacy of intervention, and related 
                research; and
                    ``(B) establish a program, or expand existing 
                programs, of research and development into congenital 
                Cytomegalovirus diagnostics, prevention, treatments 
                including public health awareness campaigns, risk 
                reduction, and vaccine development, and cures or 
                treatments (during pregnancy and after birth).''.

SEC. 3. ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND 
              CHILDREN.

    Section 1111(b) of the Public Health Service Act (42 U.S.C. 300b-
10(b)) is amended--
            (1) in paragraph (7) by striking ``and'' after the 
        semicolon;
            (2) by redesignating paragraph (8) as paragraph (9); and
            (3) by inserting after paragraph (7) the following:
            ``(8) carry out activities under section 1116A; and''.
                                 <all>
```